Related Experiment Video
Updated: Jan 29, 2026

Author Spotlight: Accurately Assessing Thyroid Hormone-Driven Motor Alterations in Mouse
Published on: October 6, 2023
Genetic and Pharmacological Targeting of Transcriptional Repression in Resistance to Thyroid Hormone Alpha
Bernard Freudenthal1, Samiksha Shetty1, Natalie C Butterfield1
11 Molecular Endocrinology Laboratory, Department of Medicine, Imperial College London, London, United Kingdom.
Abstract:
Thyroid hormones act in bone and cartilage via thyroid hormone receptor alpha (TRα). In the absence of triiodothyronine (T3), TRα interacts with co-repressors, including nuclear receptor co-repressor-1 (NCoR1), which recruit histone deacetylases (HDACs) and mediate transcriptional repression. Dominant-negative mutations of TRα cause resistance to thyroid hormone alpha (RTHα; OMIM 614450), characterized by excessive repression of T3 target genes leading to delayed skeletal development, growth retardation, and bone dysplasia. Treatment with thyroxine has been of limited benefit, even in mildly affected individuals, and there is a need for new therapeutic strategies. It was hypothesized that (i) the skeletal manifestations of RTHα are mediated by the persistent TRα/NCoR1/HDAC repressor complex containing mutant TRα, and (ii) treatment with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) would ameliorate these manifestations. The skeletal phenotypes of (i) Thra1 mice, a well characterized model of RTHα; (ii) Ncor1 mice, which express an NCoR1 mutant that fails to interact with TRα; and (iii) Thra1 double-mutant adult mice were determined. Wild-type, Thra1, Ncor1, and Thra1 double-mutant mice were also treated with SAHA to determine whether HDAC inhibition results in amelioration of skeletal abnormalities. Thra1 mice had a severe skeletal dysplasia, characterized by short stature, abnormal bone morphology, and increased bone mineral content. Despite normal bone length, Ncor1 mice displayed increased cortical bone mass, mineralization, and strength. Thra1 double-mutant mice displayed only a small improvement of skeletal abnormalities compared to Thra1 mice. Treatment with SAHA to inhibit histone deacetylation had no beneficial or detrimental effects on bone structure, mineralization, or strength in wild-type or mutant mice. These studies indicate treatment with SAHA is unlikely to improve the skeletal manifestations of RTHα. Nevertheless, the findings (i) confirm that TRα1 has a critical role in the regulation of skeletal development and adult bone mass, (ii) suggest a physiological role for alternative co-repressors that interact with TR in skeletal cells, and (iii) demonstrate a novel role for NCoR1 in the regulation of adult bone mass and strength.
Insights
Histone deacetylase inhibitor SAHA did not improve skeletal dysplasia in a mouse model of resistance to thyroid hormone alpha (RTHα). This suggests SAHA is not a viable treatment for RTHα-related bone abnormalities.
Area of Science:
- Endocrinology
- Skeletal Biology
- Molecular Genetics
Background:
- Thyroid hormone receptor alpha (TRα) regulates bone and cartilage development.
- Mutations in TRα cause resistance to thyroid hormone alpha (RTHα), leading to skeletal dysplasia.
- Current treatments for RTHα offer limited benefit, necessitating new therapeutic approaches.
Purpose of the Study:
- To investigate the role of the TRα/NCoR1/HDAC repressor complex in RTHα skeletal manifestations.
- To determine if HDAC inhibition via SAHA can ameliorate RTHα-induced skeletal abnormalities.
Main Methods:
- Phenotypic analysis of Thra1 (RTHα model), Ncor1, and double-mutant mice.
- SAHA treatment in wild-type and mutant mice to assess effects on bone structure and strength.
- Histological and densitometric analyses of bone tissues.
Main Results:
- Thra1 mice exhibited severe skeletal dysplasia, short stature, and abnormal bone morphology.
- Ncor1 mice showed increased cortical bone mass and strength despite normal bone length.
- SAHA treatment did not improve, nor worsen, skeletal phenotypes in any mouse group.
Conclusions:
- SAHA is unlikely to be effective in treating the skeletal manifestations of RTHα.
- TRα plays a critical role in skeletal development and adult bone mass regulation.
- NCoR1 is involved in regulating adult bone mass and strength, suggesting roles for alternative co-repressors.
Related Concept Videos
Functions of Thyroid Hormones
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Types of Hormones
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Hormonal Regulation

